Bioxcel therapeutics announces serenity at-home pivotal phase 3 safety trial met its primary endpoint in support of snda submission for label expansion of igalmi®

Bxcl501 achieved serenity at-home's primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia

BTAI Ratings Summary

BTAI Quant Ranking